Valdecoxib (Bextra) is as effective as oxycodone/acetaminophen in reducing pain following oral surgery

Summary

Subjects

A total of 406 subjects were randomized into 2 similarly designed postoperative pain studies. Subjects were male and female healthy young adults undergoing elective extraction of partially or completely impacted third molars.

Exposure

Following extraction of impacted third molars, participants received a single oral dose of placebo, valdecoxib 20 mg. valdecoxib 40 mg, or a combination of oxycodone 10 mg and acetaminophen 1000 mg.

Main Outcome Measure

Analgesic efficacy was measured by standard outpatient clinical testing methods.1 Visual analog and categorical scales of pain intensity and pain relief were used. The need and timing for rescue medications was recorded to provide an additional measure of analgesic efficacy. Safety data were collected for the number and frequency of adverse events during the 24-hour treatment and at the 1-week postoperative visit.

Main Results

All active treatments were found to be more effective than the placebo treatment. The valdecoxib analgesic response continued for a longer period of time than the combination of oxycodone 10 mg and acetaminophen 1000 mg. The incidence of reported adverse drug reactions (ie, nausea, dizziness, headache, vomiting, somnolence) in both studies indicated that the valdecoxib treatment groups had fewer gastrointestinal and central nervous system adverse reactions.

No full text is available. To read the body of this article, please view the PDF online.

Article Outline

• Summary

• References

• Copyright

References

1.. 1.Cooper SA, Beaver WT. A model to evaluate mild analgesics in oral surgery outpatients. Clin Pharmacol Ther. 1976;20:241–250. MEDLINE

2.. 2.Jackson DL, Roszkowski MT, Moore PA. Management of acute postoperative. In: Frost DE, Hersh E, Levin LM editor. Oral and maxillofacial surgery. W B Saunders; 2000;p. 114–140.

3.. 3.Moore PA, Hersh EV. Celecoxib and rofecoxib: the role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001;132:451–456. MEDLINE

4.. 4.Mahmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardin PJ. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo-and active-comparator-controlled clinical trial. Clin Ther. 1999;21:1653–1663. MEDLINE | CrossRef

5.. 5.Morrison BW, Christensen S, Weiying Y, Brown J, Amlani S, Seidenberg B. Analgesic efficacy of the cyclooxygenase-2-sepcific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Therap. 1999;21:943–951.

6.. 6.Ehlich EW, Dallob A, Lepeleire ID, Van Hecken A, Riendau D, Yaun W, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental model. Clin Pharmacol Ther. 1999;6:83–92.

7.. 7.Henry D, Drew A, Beuzeville . Adverse drug reactions in the gastrointestinal system attributed to ibuprofen. In: Rainsford KD, Powanda MC editor. Safety and efficacy of non-prescription (OTC) analgesics and NSAIDs. Philadelphia: Kluwer Academic Publishers; 1998;p. 19–45.

8.. 8.Hersh EV, Moore PA, Ross GL. Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther. 2000;22:500–548. MEDLINE | CrossRef

9.. 9.Carson JL, Strom BL, Morse ML. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1987;147:1054–1059. MEDLINE

10.. 10.Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. JAMA. 2000;284:1247–1255. MEDLINE | CrossRef

11.. 11.Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Eng J Med. 2000;343:1520–1528.

12.. 12.[letter] New safety information pertaining to BEXTRA (valdecoxib). #UD0029719 Hingham (Mass): Pharmacia Corp and Pfizer Inc; 2002, Sept;.

University of Pittsburgh School of Dental Medicine Pittsburgh, Pa, USA

PII: S1532-3382(03)80095-7

doi:10.1067/med.2003.6

5 of 30